ACE2 in tumor cells and tumor vasculature: Negligible intercellular transfer from cancer cells into endothelial cells

Zhi‐Jie Liu, Yan Mei, Jiangli Lu, Jiabin Lu, Yun Cao, Muyan Cai, Lisheng Zheng, Ming‐Dian Wang, Li‐Xia Peng, Yang Li, Bi‐Jun Huang, Jin-Ping Yun, Chao‐Nan QianVisualized 2021 · DOI

Abstract

Cancer patients are more susceptible to severe coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Angiotensin-converting enzyme 2 (ACE2) is the functional host receptor for SARS-CoV-2 entering into human cells. Bioinformatics’ analyses have revealed that ACE2 is upregulated in some cancer cells. In the present study, we evaluated ACE2 protein expression levels in several common malignancies compared to non-cancerous normal tissues. ACE2 expression was elevated in colorectal adenocarcinoma, pancreatic adenocarcinoma, gastric adenocarcinoma, and papillary renal cell carcinoma cancer. Yet, it was suppressed in chromophobe renal cell carcinoma, testicular germ cell tumors, and papillary thyroid carcinoma. Two tumor tissue microarrays were used to evaluate the prognostic value of ACE2 expression in patients with gastric adenocarcinoma, and colorectal adenocarcinoma without COVID-19. No significant survival benefit was found for patients with overexpression of ACE2 in the tumor. In the tumor vasculature, ACE2 expression was observed in only 54% of the tumor micro-vessels. Using an in vitro co-culture of endothelial cells and tumor cells overexpressing fusion protein ACE2-red fluorescent protein, we did not observe any clear and convincing intercellular transfer of ACE2 from cancer cells into endothelial cells. In summary, alteration of ACE2 expression was found in common malignancies, but there is no evidence of intercellular transfer of ACE2 from cancer cells to endothelial cells.

Introduction

Since the emergence of the COVID-19 pandemic, clinical observations have consistently indicated that individuals with cancer are at a significantly higher risk for severe infection and mortality. The primary entry point for the SARS-CoV-2 virus is the Angiotensin-converting enzyme 2 (ACE2) receptor. While bioinformatics studies have suggested that ACE2 is upregulated in various malignancies, it remained unclear whether cancer cells overexpressing ACE2 could transfer this protein to the endothelial cells lining tumor blood vessels. Such a transfer could theoretically increase vascular susceptibility to viral infection, potentially explaining the heightened severity of COVID-19 in cancer patients. This study aimed to map ACE2 expression across multiple cancer types and investigate the possibility of intercellular protein transfer.

Methods

The study utilized a comprehensive dataset from the Sun Yat-sen University Cancer Center (SYSUCC), encompassing 1,175 tumor samples and 1,058 matched normal tissues across various organs, including the thyroid, stomach, pancreas, colon, rectum, kidney, and testis.

ACE2 protein levels were quantified using immunohistochemistry (IHC) on paraffin-embedded tissues. For gastric and colorectal cancers, tissue microarrays (TMAs) were employed to correlate ACE2 expression with patient survival in cohorts of 475 and 420 cases, respectively. To test the intercellular transfer hypothesis, gastric (MGC803) and pancreatic (Capan-2) cancer cells were engineered to express an ACE2-RFP (Red Fluorescent Protein) fusion protein. These cells were co-cultured with Human Microvascular Endothelial Cells (HMVECs) and monitored via high-content confocal microscopy every 15 minutes for 24 hours. Statistical analyses included Wilcoxon signed-rank tests for tissue comparisons and Kaplan-Meier methods for survival analysis.

Results

Heterogeneous ACE2 Expression Across Malignancies

The investigation revealed that ACE2 expression is highly cancer-specific. Significant upregulation of ACE2 protein was observed in colorectal, pancreatic, and gastric adenocarcinomas, as well as papillary renal cell carcinoma, compared to normal tissues ($P < 0.01$). Conversely, ACE2 was significantly downregulated in chromophobe renal cell carcinoma, testicular seminoma, and papillary thyroid carcinoma ($P < 0.01$).

Representative IHC staining of ACE2 in various tumor and normal tissues, demonstrating the range of expression levels from strong to weak across different cancer types.

Prognostic Impact and Vascular Expression

In the absence of COVID-19, ACE2 expression levels did not serve as a significant prognostic marker. Survival analysis for gastric cancer ($P = 0.339$) and colorectal cancer ($P = 0.093$) showed no statistically significant correlation between ACE2 levels and overall survival, although a non-significant trend toward improved survival was noted in the colorectal cohort.

Overall survival analysis based on ACE2 expression in gastric and colorectal adenocarcinoma, showing no statistically significant survival benefit for patients with high ACE2 expression.

Furthermore, ACE2 expression in the tumor vasculature was found to be heterogeneous, appearing in only approximately 54% of tumor micro-vessels. This suggests that vascular vulnerability to SARS-CoV-2 may vary significantly within tumor tissues.

Negligible Intercellular Transfer

A key finding of this study was the lack of evidence for the intercellular transfer of ACE2. During the 24-hour time-lapse imaging of co-cultured cancer and endothelial cells, no red fluorescence (ACE2-RFP) was observed to move from the cancer cells into the HMVECs. This suggests that the ACE2 present on tumor vasculature is likely endogenous to the endothelial cells rather than being acquired from neighboring tumor cells.

Discussion and Conclusion

While certain cancers exhibit significantly elevated levels of the SARS-CoV-2 receptor ACE2, this study indicates that tumor-driven "sharing" of these receptors with the vasculature is not a primary mechanism for increased COVID-19 risk. The findings suggest that vascular ACE2 expression is independent of tumor cell expression levels.

The study's limitations include the relatively short 24-hour window for co-culture experiments and the inherent differences between in vitro models and the complex in vivo tumor microenvironment, which includes blood flow and mechanical stresses. Future research should explore these dynamics over longer periods and across a broader range of organ-specific endothelial cells. In conclusion, while ACE2 levels are altered in common malignancies, there is no convincing evidence of its transfer from cancer cells to the tumor blood supply.

Summary updated

Abstract

Cancer patients are more susceptible to severe coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Angiotensin-converting enzyme 2 (ACE2) is the functional host receptor for SARS-CoV-2 entering into human cells. Bioinformatics’ analyses have revealed that ACE2 is upregulated in some cancer cells. In the present study, we evaluated ACE2 protein expression levels in several common malignancies compared to non-cancerous normal tissues. ACE2 expression was elevated in colorectal adenocarcinoma, pancreatic adenocarcinoma, gastric adenocarcinoma, and papillary renal cell carcinoma cancer. Yet, it was suppressed in chromophobe renal cell carcinoma, testicular germ cell tumors, and papillary thyroid carcinoma. Two tumor tissue microarrays were used to evaluate the prognostic value of ACE2 expression in patients with gastric adenocarcinoma, and colorectal adenocarcinoma without COVID-19. No significant survival benefit was found for patients with overexpression of ACE2 in the tumor. In the tumor vasculature, ACE2 expression was observed in only 54% of the tumor micro-vessels. Using an in vitro co-culture of endothelial cells and tumor cells overexpressing fusion protein ACE2-red fluorescent protein, we did not observe any clear and convincing intercellular transfer of ACE2 from cancer cells into endothelial cells. In summary, alteration of ACE2 expression was found in common malignancies, but there is no evidence of intercellular transfer of ACE2 from cancer cells to endothelial cells.
BibTeX
@inproceedings{liu2021ace,
  author = {Zhi‐Jie Liu and Yan Mei and Jiangli Lu and Jiabin Lu and Yun Cao and Muyan Cai and Lisheng Zheng and Ming‐Dian Wang and Li‐Xia Peng and Yang Li and Bi‐Jun Huang and Jin-Ping Yun and Chao‐Nan Qian},
  title = {{ACE2 in tumor cells and tumor vasculature: Negligible intercellular transfer from cancer cells into endothelial cells}},
  booktitle = {Visualized},
  year = {2021},
  doi = {10.1051/vcm/2021004},
}
Figure